Generation Bio Management
Management criteria checks 2/4
Generation Bio's CEO is Yalonda Howze, appointed in Oct 2025, has a tenure of less than a year. directly owns 0.035% of the company’s shares, worth $13.04K. The average tenure of the management team and the board of directors is 3.3 years and 7.8 years respectively.
Key information
Yalonda Howze
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.03% |
| Management average tenure | 3.3yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky
Nov 14
There Is A Reason Generation Bio Co.'s (NASDAQ:GBIO) Price Is Undemanding
Jul 14Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29%
Mar 16We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$63m |
| Jun 30 2025 | n/a | n/a | -US$72m |
| Mar 31 2025 | n/a | n/a | -US$72m |
| Dec 31 2024 | n/a | n/a | -US$132m |
| Sep 30 2024 | n/a | n/a | -US$145m |
| Jun 30 2024 | n/a | n/a | -US$158m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$1m | US$340k | -US$127m |
Compensation vs Market: Insufficient data to establish whether Yalonda's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Yalonda's compensation with company performance.
CEO
Yalonda Howze (53 yo)
Ms. Yalonda Howze, J.D., served as Chief Legal Officer and Secretary at Generation Bio Co. from April 05, 2023 until October 31, 2025 and serves as its Interim Chief Executive Officer and President since O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Operating Officer | 3.8yrs | US$931.96k | 0.054% $ 20.3k | |
| Chief Scientific Officer | 3.3yrs | US$931.76k | 0.21% $ 78.6k | |
| Interim CEO & President | less than a year | US$1.21m | 0.035% $ 13.0k | |
| Co-Founder | 9.2yrs | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Chief Financial Officer | no data | no data | 0.028% $ 10.4k | |
| Chief Human Resources Officer | 2.8yrs | no data | no data | |
| Senior VP & Head of Business Development | no data | no data | no data |
Experienced Management: GBIO's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 7.6yrs | US$210.48k | 0% $ 0 | |
| Independent Director | no data | US$251.48k | 0% $ 0 | |
| Independent Director | 8yrs | US$213.98k | 0.20% $ 73.1k | |
| Independent Director | 7.4yrs | US$221.48k | 0.79% $ 297.3k | |
| Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Independent Director | 8yrs | US$213.98k | 0.55% $ 206.9k | |
| Chairman of the Board | 8.2yrs | US$1.81m | 2.78% $ 1.0m | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8yrs | US$213.98k | 0.32% $ 118.7k | |
| Independent Director | 4.8yrs | US$214.48k | 0.014% $ 5.3k | |
| Independent Director | 8yrs | US$213.98k | 0.071% $ 26.4k | |
| Member of Scientific Advisory Board | 6.5yrs | no data | no data |
Experienced Board: GBIO's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 05:22 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Generation Bio Co. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Farzin Haque | Jefferies LLC |